COVID Antibody Products May Get To Use Viral Load As Surrogate For Mutant-Targeted Versions

 
• By Sue Sutter

Former US FDA commissioners say that data for Lilly and Regeneron’s authorized mABs suggesting that reduced viral load correlates with clinical benefit potentially paves the way for emergency authorization or accelerated approval of mABs specifically designed to target emerging variants of the SARS-CoV-2 virus.

Footrace
Monoclonal antibody developers and regulators are trying to keep up with changes in the coronavirus that causes COVID-19. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards